EGFR and carcinoma: Particularly, when combining the three orthogonal sources of information, the full cellular MoAs of Afatinib in the cell line A431 is revealed: Afatinib binds to EGFR with a KD of ~10 nM in cells (50% target engagement), inhibiting the main driver of this carcinoma and leading to the shut-down of key downstream survival signals.